You are here: Industry Insights > Market News > Philip Morris Heats Up Race for Vectura With $1.4 Billion Bid

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Philip Morris Heats Up Race for Vectura With $1.4 Billion Bid

firstwordpharmaAugust 09, 2021

Tag: Philip Morris , Vectura , Bloomberg

Favorites

Philip Morris International on Sunday bid £1.65 per share for Vectura Group, after Carlyle on Friday offered £1.50 per share, Bloomberg reported.

The new bid values Vectura's shares at about £1 billion pounds ($1.4 billion).

Previous:Potential drug against COVID-19 found among tapeworm medications

Next:FDA to allow export of certain lots of AstraZeneca COVID-19 vaccine made at Baltimore plant

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Philip Morris Heats Up Race for Vectura With $1.4 Billion Bid | Pharmasources.com

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

Philip Morris Heats Up Race for Vectura With $1.4 Billion Bid

Related News

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

You may like